5/7/2025

Comprehensive Analysis

• Earnings Beat with Revenue Miss and Guidance Upgrade: Cencora’s Q2 adjusted EPS of $4.42 exceeded estimates by $0.31, driven by U.S. Healthcare Solutions growth (11.4% revenue increase) and cost adjustments. However, revenue of $75.45B fell short of the $75.68B estimate, reflecting softer international performance and inventory consolidation post-RCA acquisition. The company raised FY2025 adjusted EPS guidance to $15.70–$15.95, signaling confidence in growth, but $6.3B in new debt to fund the RCA acquisition has elevated interest expenses by 62.2%, raising leverage concerns.
• Segment Divergence and Margin Pressures: U.S. Healthcare Solutions outperformed with 22.8% operating income growth, fueled by GLP-1 product demand and specialty distribution, while International Healthcare Solutions declined 17.3% in operating income due to weaker global logistics and European distribution. This imbalance could pressure overall margins if international recovery lags, particularly as the sector ETF remains above its 200-week SMA, indicating broader market strength.